[go: up one dir, main page]

AR025735A1 - Compuestos terapeuticos - Google Patents

Compuestos terapeuticos

Info

Publication number
AR025735A1
AR025735A1 ARP000104956A ARP000104956A AR025735A1 AR 025735 A1 AR025735 A1 AR 025735A1 AR P000104956 A ARP000104956 A AR P000104956A AR P000104956 A ARP000104956 A AR P000104956A AR 025735 A1 AR025735 A1 AR 025735A1
Authority
AR
Argentina
Prior art keywords
hydrogen
alkyl
optionally substituted
alkoxy
compound
Prior art date
Application number
ARP000104956A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR025735A1 publication Critical patent/AR025735A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de formula (1) o una sal, éster, amida o prodroga del mismo; donde X es O, o S, S(O), S(O)2 o NR6 donde R6 es hidrogeno o alquilo C1-6; R5 esun anillo aromático de 6 miembros opcionalmente sustituido que contiene al menos un átomo de nitrogeno, y R1, R2, R3, R4 se seleccionan independientementeentre halogeno, ciano, nitro, alquilsulfanilo C1-3, -N(OH)R7- (donde R7 es hidrogeno o alquilo C1-3), o R9X1- (donde X1 representa un enlace directo, -O-,-CH2-, -OC(O)-, -C(O)-, -S-, -SO-, -SO2-, -NR10C(O)-, -C(O)NR11-, -SO2NR12-, -NR13SO2- o -NR14- (donde R10, R11, R12, R13 y R14 representan cada unoindependientemente hidrogeno, alquilo C1-3 o alcoxi C1-3-alquilo C2-3), y R9 es hidrogeno, hidrocarbilo opcionalmente sustituido, heterociclo opcionalmentesustituido o alcoxi opcionalmente sustituido; siempre que al menos uno entre R2 o R3 sea distinto de hidrogeno. Estos compuestos inhiben la aurora 2 quinasa yson utiles en la preparacion de medicamentos para el tratamiento de enfermedades proliferativas tales como el cáncer. También se presenta una composicionfarmacéutica en base al compuesto indicado.
ARP000104956A 1999-09-21 2000-09-21 Compuestos terapeuticos AR025735A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9922171.5A GB9922171D0 (en) 1999-09-21 1999-09-21 Chemical compounds

Publications (1)

Publication Number Publication Date
AR025735A1 true AR025735A1 (es) 2002-12-11

Family

ID=10861217

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104956A AR025735A1 (es) 1999-09-21 2000-09-21 Compuestos terapeuticos

Country Status (24)

Country Link
US (1) US7235559B1 (es)
EP (1) EP1218355A1 (es)
JP (1) JP2003509500A (es)
KR (1) KR20020030123A (es)
CN (1) CN1391563A (es)
AR (1) AR025735A1 (es)
AU (1) AU762697B2 (es)
BG (1) BG106526A (es)
BR (1) BR0014137A (es)
CA (1) CA2384296A1 (es)
CO (1) CO5200783A1 (es)
CZ (1) CZ20021008A3 (es)
EE (1) EE200200118A (es)
GB (1) GB9922171D0 (es)
HK (1) HK1046685A1 (es)
HU (1) HUP0300205A3 (es)
IL (1) IL148496A0 (es)
IS (1) IS6310A (es)
NO (1) NO20021400L (es)
PL (1) PL354870A1 (es)
SK (1) SK3872002A3 (es)
TR (1) TR200200717T2 (es)
WO (1) WO2001021597A1 (es)
ZA (1) ZA200202232B (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2283311C2 (ru) * 2000-06-28 2006-09-10 Астразенека Аб Замещенные производные хиназолина и их применение в качестве ингибиторов
JP4564713B2 (ja) 2000-11-01 2010-10-20 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 窒素性複素環式化合物、ならびに窒素性複素環式化合物およびその中間体を作製するための方法
JP2002293773A (ja) * 2001-03-30 2002-10-09 Sumika Fine Chemicals Co Ltd キナゾリン誘導体の製造方法
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
RU2323215C2 (ru) * 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
EP1471910A2 (en) 2002-01-17 2004-11-03 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US7176310B1 (en) 2002-04-09 2007-02-13 Ucb Sa Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
US7560558B2 (en) * 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
ES2300619T3 (es) 2002-11-04 2008-06-16 Astrazeneca Ab Derivados de quinolina como inhibidores de src tirosina quinasa.
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003285614B2 (en) 2002-12-20 2009-05-14 Pfizer Products, Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
AU2003290279A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab Quinazoline derivatives
AU2003292435A1 (en) * 2002-12-23 2004-07-14 Astrazeneca Ab 4- (pyridin-4-ylamino) -quinazoline derivatives as anti-tumor agents
AU2003299943A1 (en) * 2002-12-23 2004-07-22 Ariad Pharmaceuticals, Inc. Heterocycles and uses thereof
CN1753889A (zh) 2002-12-24 2006-03-29 阿斯利康(瑞典)有限公司 喹唑啉化合物
PL221490B1 (pl) 2002-12-24 2016-04-29 Astrazeneca Ab Pochodne fosfonooksychinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
US20060058325A1 (en) * 2002-12-24 2006-03-16 Astrazeneca Ab Therapeutic quniazoline derivatives
CL2004000797A1 (es) * 2003-04-16 2005-05-27 Astrazeneca Ab Compuestos derivados de quinazolina, inhibidores de aurora quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para preparar un medicamento para tratar cancer colorrectal, de mama, de pulmon, de prostata, de vejiga, renal o panc
JP2006526599A (ja) * 2003-06-02 2006-11-24 アストラゼネカ アクチボラグ 癌のような増殖性疾患の治療のためのオーロラキナーゼインヒビターとしての（３−（（キナゾリン−４−イル）アミノ）−１ｈ−ピラゾール−１−イル）アセトアミド誘導体及び関連化合物
WO2004108707A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyridazinil quinazoline derivatives for use in the treatment of tumours
WO2004108711A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab Pyrazinil quinazoline derivatives for use in the treatment of tumours
WO2004108710A1 (en) * 2003-06-05 2004-12-16 Astrazeneca Ab 4-pyrimidinyl quinazoline derivatives for use in the treatment of tumours
TW200505452A (en) * 2003-06-17 2005-02-16 Astrazeneca Ab Chemical compounds
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
DK1660090T3 (da) * 2003-08-14 2012-12-17 Array Biopharma Inc Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005037825A2 (en) 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
AU2004285052A1 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (AZA) quinoline derivatives as capsaicin receptor agonists
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
JP2007537230A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の処置用のピリミジン誘導体
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1778669A2 (en) 2004-08-18 2007-05-02 Takeda San Diego, Inc. Kinase inhibitors
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
ES2319462T3 (es) * 2005-03-28 2009-05-07 Bristol-Myers Squibb Company Inhibidores competitivos de atp cinasas.
KR20070113286A (ko) 2005-04-14 2007-11-28 에프. 호프만-라 로슈 아게 아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US20090076075A1 (en) * 2006-03-02 2009-03-19 Frederic Henri Jung Quinoline derivatives
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP2137177B1 (en) * 2007-04-05 2014-05-07 Amgen, Inc Aurora kinase modulators and method of use
CN101215274B (zh) * 2007-12-27 2011-05-04 上海北卡医药技术有限公司 N取代吗啉类有机化合物的制备工艺
CN101939316B (zh) 2008-02-07 2013-10-02 贝林格尔.英格海姆国际有限公司 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
BRPI0920261A8 (pt) * 2008-10-14 2016-01-19 Xi Ning Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
MX2011009926A (es) * 2009-03-21 2012-01-27 Ning Xi Derivados de amino esteres, sales de los mismos, y metodos de uso.
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
GB201021103D0 (en) * 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
CN103304489B (zh) * 2012-03-16 2015-03-11 中国农业科学院兰州畜牧与兽药研究所 嘧啶苯甲酰胺类化合物及其制备和应用
DK3046584T3 (en) 2013-09-16 2017-10-02 Astrazeneca Ab THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
HUE050761T2 (hu) 2014-01-01 2021-01-28 Medivation Tech Llc Vegyületek és alkalmazási eljárások
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
EP3184507A1 (en) * 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Preparation of phenyl compounds
DK3570834T3 (en) 2017-01-11 2022-02-28 Alkermes Inc Bicyclic inhibitors of histone deacetylase
AU2018313094A1 (en) 2017-08-07 2020-02-20 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
CN110746398A (zh) * 2019-10-18 2020-02-04 刘沛友 4-杂环取代喹唑啉类衍生物及其制备方法和用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU3630100A (en) * 1999-03-19 2000-10-09 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
TR200200717T2 (tr) 2002-06-21
ZA200202232B (en) 2003-08-27
PL354870A1 (en) 2004-03-08
CZ20021008A3 (cs) 2002-06-12
IS6310A (is) 2002-03-19
WO2001021597A1 (en) 2001-03-29
HK1046685A1 (zh) 2003-01-24
IL148496A0 (en) 2002-09-12
KR20020030123A (ko) 2002-04-22
NO20021400D0 (no) 2002-03-20
NO20021400L (no) 2002-05-06
US7235559B1 (en) 2007-06-26
HUP0300205A3 (en) 2003-08-28
AU762697B2 (en) 2003-07-03
EP1218355A1 (en) 2002-07-03
AU7301900A (en) 2001-04-24
EE200200118A (et) 2003-04-15
GB9922171D0 (en) 1999-11-17
BG106526A (en) 2002-10-31
BR0014137A (pt) 2002-05-21
CA2384296A1 (en) 2001-03-29
CO5200783A1 (es) 2002-09-27
SK3872002A3 (en) 2002-12-03
CN1391563A (zh) 2003-01-15
JP2003509500A (ja) 2003-03-11
HUP0300205A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
AR025735A1 (es) Compuestos terapeuticos
AR038762A1 (es) Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
AR039203A1 (es) Derivados de quinazolina
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
HUP0303146A2 (hu) Protein kináz gátló hatású 3-(4-amido-pirrol-2-il-metilidén)-2-indolinon származékok és ezeket tartalmazó gyógyszerkészítmények
CA2545427A1 (en) Selective kinase inhibitors
SE0202463D0 (sv) Novel compounds
UY27097A1 (es) Derivados del indol
UY27592A1 (es) Nuevo uso
AR024918A1 (es) Derivados de ciclobuteno, su preparacion y sus usos terapeuticos.
AR018915A1 (es) Inhibidores de proteasas diacilhidrazinicos, composicion farmaceutica que la comprenden, usos de los mismos para la manufactura de un medicamento, unprocedimiento de fabricacion de dichos compuestos
AR050698A1 (es) Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto
MY129176A (en) Tetrahydro gamma-carbolines
PT902684E (pt) Derivados hexa-hidro-pirido(4,3-b)indolo utilizados como farmacos antipsicoticos
AR037521A1 (es) Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion
CO5160241A1 (es) 2-aminopiridinas que contienen sustituyentes de tipo anillo condensado
AR050711A1 (es) Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
AR012097A1 (es) UN COMPUESTO DERIVADO DE 2,3-DIHIDROFURO[3,2-B]PIRIDINA, UN PROCEDIMIENTO DE PREPARACIoN DE DICHO COMPUESTO Y UN MEDICAMENTO Y UNA COMPOSICONFARMACEUTICA QUE LO COMPRENDEN.
AR054231A1 (es) Composiciones farmaceuticas
AR016594A1 (es) DERIVADOS DE 3,4,5,7-TETRAHIDRO-PIRROLO[3',4':4,5]TIENO[2,3-d]PIRIMIDINA 3-SUSTITUIDOS Y SU USO PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
ES2149193T3 (es) Compuestos heterociclicos sustituidos con alquilo.
NO932382D0 (no) Heterocykliske forbindelser